Clinical trial
A Study of Nivolumab by Itself or Nivolumab Combined With Ipilimumab in Patients…
NCT01928394 · Bristol-Myers Squibb, Industry · Completed
Key facts
| NCT number | NCT01928394 |
|---|---|
| Title | A Study of Nivolumab by Itself or Nivolumab Combined With Ipilimumab in Patients With Advanced or Metastatic Solid Tumors |
| Official title | A Phase 1/2, Open-label Study of Nivolumab Monotherapy or Nivolumab Combined With Ipilimumab in Subjects With Advanced or Metastatic Solid Tumors |
| Lead sponsor | Bristol-Myers Squibb, Industry |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Advanced or Metastatic Solid Tumors |
| Intervention type | Biological, Drug |
| Interventions | Nivolumab, Ipilimumab, Cobimetinib |
| Enrollment | 1,163 |
| Start date | Oct 24, 2013 |
| Primary completion | Feb 5, 2019 |
| Completion | Nov 18, 2024 |
| First posted | Aug 23, 2013 |
| Last update posted | Dec 27, 2024 |
| Countries | Canada, Denmark, Finland, Germany, Italy, Spain, United Kingdom, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: